Galapagos (GLPG) Competitors $26.74 +0.01 (+0.04%) Closing price 04:00 PM EasternExtended Trading$26.74 0.00 (0.00%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends GLPG vs. LEGN, BBIO, AXSM, BPMC, TLX, ELAN, LNTH, NUVL, CYTK, and VRNAShould you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), Cytokinetics (CYTK), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. Galapagos vs. Legend Biotech BridgeBio Pharma Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Elanco Animal Health Lantheus Nuvalent Cytokinetics Verona Pharma Galapagos (NASDAQ:GLPG) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership. Which has more volatility and risk, GLPG or LEGN? Galapagos has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Which has better earnings and valuation, GLPG or LEGN? Galapagos has higher revenue and earnings than Legend Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalapagos$298.31M5.91$80.16MN/AN/ALegend Biotech$285.14M25.42-$518.25M-$0.95-41.78 Does the MarketBeat Community prefer GLPG or LEGN? Galapagos received 381 more outperform votes than Legend Biotech when rated by MarketBeat users. However, 72.03% of users gave Legend Biotech an outperform vote while only 63.84% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformGalapagosOutperform Votes46663.84% Underperform Votes26436.16% Legend BiotechOutperform Votes8572.03% Underperform Votes3327.97% Do institutionals and insiders believe in GLPG or LEGN? 32.5% of Galapagos shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer GLPG or LEGN? Galapagos currently has a consensus price target of $26.75, suggesting a potential upside of 0.04%. Legend Biotech has a consensus price target of $79.50, suggesting a potential upside of 100.28%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galapagos 5 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.44Legend Biotech 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GLPG or LEGN more profitable? Galapagos has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Galapagos' return on equity of 0.00% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets GalapagosN/A N/A N/A Legend Biotech -66.92%-29.69%-19.45% Does the media prefer GLPG or LEGN? In the previous week, Galapagos had 10 more articles in the media than Legend Biotech. MarketBeat recorded 14 mentions for Galapagos and 4 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 1.36 beat Galapagos' score of 0.14 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galapagos 2 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGalapagos beats Legend Biotech on 9 of the 16 factors compared between the two stocks. Get Galapagos News Delivered to You Automatically Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLPG vs. The Competition Export to ExcelMetricGalapagosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.76B$7.05B$5.80B$8.94BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.0926.4118.84Price / Sales5.91314.10450.1476.68Price / CashN/A67.8344.0437.47Price / Book0.566.757.634.64Net Income$80.16M$138.11M$3.18B$245.69M7 Day Performance5.11%-1.99%-1.82%-2.59%1 Month Performance12.21%-1.51%0.22%-2.30%1 Year Performance-30.85%-3.20%17.25%13.71% Galapagos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLPGGalapagos0.2296 of 5 stars$26.74+0.0%$26.75+0.0%-32.2%$1.76B$298.31M0.001,123LEGNLegend Biotech2.6195 of 5 stars$36.42+0.1%$79.50+118.3%-35.2%$6.65B$285.14M-38.341,800Positive NewsGap UpBBIOBridgeBio Pharma4.7364 of 5 stars$34.90+10.6%$49.08+40.6%+2.4%$6.60B$9.30M-14.48400Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap UpAXSMAxsome Therapeutics4.5395 of 5 stars$131.15-0.4%$147.13+12.2%+59.2%$6.36B$270.60M-20.08380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBPMCBlueprint Medicines3.0196 of 5 stars$93.94-1.3%$123.83+31.8%+3.4%$5.97B$249.38M-44.52640Earnings ReportTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.19-0.6%$22.00+28.0%N/A$5.79B$637.08M0.00N/ANews CoverageGap UpELANElanco Animal Health4.1542 of 5 stars$11.26-3.4%$16.29+44.7%-31.0%$5.57B$4.42B28.159,300Analyst ForecastLNTHLantheus4.588 of 5 stars$79.94-2.5%$131.86+64.9%+42.3%$5.56B$1.30B13.30700Analyst RevisionNUVLNuvalent1.8522 of 5 stars$77.93-3.7%$112.36+44.2%+0.5%$5.54BN/A-22.4640Upcoming EarningsInsider TradeCYTKCytokinetics4.2215 of 5 stars$46.16+10.9%$82.00+77.6%-33.5%$5.45B$7.53M-8.58250High Trading VolumeVRNAVerona Pharma1.9573 of 5 stars$64.21+4.1%$57.14-11.0%+277.6%$5.13B$460,000.00-33.4430 Related Companies and Tools Related Companies LEGN Competitors BBIO Competitors AXSM Competitors BPMC Competitors TLX Competitors ELAN Competitors LNTH Competitors NUVL Competitors CYTK Competitors VRNA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLPG) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galapagos NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Galapagos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
